aTyr Pharma (LIFE)
(Delayed Data from NSDQ)
$1.60 USD
-0.02 (-1.23%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $1.61 +0.01 (0.63%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for aTyr Pharma, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 98 | 66 | 108 | 32 | 31 |
Receivables | 2 | 12 | 0 | 2 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 3 | 5 | 2 | 1 |
Total Current Assets | 103 | 81 | 114 | 36 | 32 |
Net Property & Equipment | 6 | 3 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 4 | 3 | 0 | 0 | 0 |
Total Assets | 121 | 96 | 116 | 39 | 36 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 3 | 1 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 9 |
Current Portion Capital Leases | 1 | 0 | 0 | 0 | 0 |
Accrued Expenses | 12 | 10 | 4 | 4 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 16 | 14 | 6 | 6 | 13 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 1 | 1 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 30 | 25 | 6 | 7 | 15 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 559 | 490 | 482 | 370 | 344 |
Retained Earnings | -468 | -418 | -372 | -339 | -322 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 90 | 71 | 109 | 31 | 21 |
Total Liabilities & Shareholder's Equity | 121 | 96 | 116 | 39 | 36 |
Total Common Equity | 90 | 71 | 109 | 31 | 21 |
Shares Outstanding | 58.50 | 29.50 | 27.70 | 11.00 | 3.80 |
Book Value Per Share | 1.55 | 2.42 | 3.94 | 2.86 | 5.53 |
Fiscal Year End for aTyr Pharma, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 98 | 102 | 109 | 114 |
Receivables | NA | 2 | 2 | 1 | 2 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 2 | 3 | 5 | 3 |
Total Current Assets | NA | 103 | 107 | 114 | 119 |
Net Property & Equipment | NA | 6 | 6 | 6 | 5 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 4 | 4 | 3 | 3 |
Total Assets | NA | 121 | 125 | 133 | 137 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 4 | 2 | 1 | 4 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 1 | 0 | 0 | 0 |
Accrued Expenses | NA | 12 | 10 | 11 | 9 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 16 | 13 | 12 | 14 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 1 | 1 | 2 | 2 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 30 | 27 | 27 | 27 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 559 | 552 | 548 | 540 |
Retained Earnings | NA | -468 | -453 | -442 | -430 |
Other Equity | NA | 0 | 0 | -1 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 90 | 98 | 106 | 110 |
Total Liabilities & Shareholder's Equity | NA | 121 | 125 | 133 | 137 |
Total Common Equity | 0 | 90 | 98 | 106 | 110 |
Shares Outstanding | 67.70 | 58.50 | 57.00 | 54.20 | 53.10 |
Book Value Per Share | 0.00 | 1.55 | 1.72 | 1.96 | 2.07 |